Amedisys Inc. (NASDAQ:AMED) was the recipient of a significant growth in short interest in October. As of October 31st, there was short interest totalling 1,612,800 shares, a growth of 77.0% from the October 14th total of 911,389 shares. Approximately 4.9% of the company’s stock are short sold. Based on an average daily volume of 324,011 shares, the short-interest ratio is currently 5.0 days.

Shares of Amedisys (NASDAQ:AMED) opened at 41.12 on Friday. The firm has a market capitalization of $1.38 billion, a PE ratio of 33.54 and a beta of 1.45. Amedisys has a 52 week low of $31.16 and a 52 week high of $55.16. The stock has a 50 day moving average of $44.49 and a 200-day moving average of $48.96.

Amedisys (NASDAQ:AMED) last announced its quarterly earnings results on Thursday, November 3rd. The company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.44 by $0.08. The firm earned $361.60 million during the quarter, compared to analyst estimates of $361.08 million. Amedisys had a net margin of 2.93% and a return on equity of 11.94%. The business’s revenue was up 10.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.34 earnings per share. Equities analysts anticipate that Amedisys will post $1.50 earnings per share for the current fiscal year.

Several hedge funds have recently made changes to their positions in AMED. Gilder Gagnon Howe & Co. LLC purchased a new stake in shares of Amedisys during the third quarter worth $42,527,000. Victory Capital Management Inc. purchased a new stake in shares of Amedisys during the third quarter worth $38,456,000. TimesSquare Capital Management LLC purchased a new stake in shares of Amedisys during the third quarter worth $19,359,000. Renaissance Technologies LLC increased its stake in shares of Amedisys by 81.1% in the first quarter. Renaissance Technologies LLC now owns 630,901 shares of the company’s stock valued at $30,498,000 after buying an additional 282,600 shares during the period. Finally, Kalmar Investments Inc. DE bought a new stake in shares of Amedisys during the third quarter valued at approximately $12,731,000. Institutional investors and hedge funds own 89.64% of the company’s stock.

AMED has been the topic of a number of research analyst reports. Mizuho raised shares of Amedisys from a “neutral” rating to a “buy” rating and set a $47.00 price objective on the stock in a research report on Friday, November 4th. They noted that the move was a valuation call. Zacks Investment Research raised shares of Amedisys from a “sell” rating to a “hold” rating in a research report on Thursday, August 4th. Jefferies Group reaffirmed a “buy” rating on shares of Amedisys in a research report on Tuesday, September 6th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Amedisys in a research report on Sunday, September 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and three have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $50.29.

Amedisys Company Profile

Amedisys, Inc (Amedisys) is a provider of home health and hospice services. The Company offers home health services to the chronic, co-morbid, aging American population. The Company operates through three segments: home health, hospice and personal care. The Company’s home health segment delivers a range of services in the homes of individuals recovering from surgery, have a chronic disability or terminal illness or need assistance with completing important personal tasks.

5 Day Chart for NASDAQ:AMED

Receive News & Stock Ratings for Amedisys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc. and related stocks with our FREE daily email newsletter.